Key takeaways
- 2 one-time gene therapies FDA-approved December 2023 — Casgevy and Lyfgenia · FDA product labeling
- 97% exa-cel (Casgevy) evaluable patients free from severe vaso-occlusive crises ≥12 months, CLIMB SCD-121 · NEJM 2024 (PMID 38661449)
- ~$2.2–3.1M one-time list price per gene therapy, plus weeks of myeloablative conditioning and apheresis · manufacturer list prices
Two one-time gene therapies approved in December 2023, Casgevy and Lyfgenia, split a ~100,000-patient US market from a hydroxyurea backbone that still reaches only a quarter of eligible patients, while voxelotor's 2024 withdrawal thins the oral disease-modifying field.
Sickle cell disease became a gene-therapy market in December 2023, when the FDA approved two one-time autologous therapies for patients aged 12 and older with recurrent vaso-occlusive disease. Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) uses CRISPR-Cas9 to edit the BCL11A enhancer and reactivate fetal hemoglobin; in the pivotal CLIMB SCD-121 study, 29 of 30 evaluable patients (97%) were free from severe vaso-occlusive crises for at least 12 months. Lyfgenia (lovotibeglogene autotemcel, bluebird bio) adds an anti-sickling β-globin gene via a lentiviral vector and carries an FDA boxed warning for hematologic malignancy. Both require weeks of myeloablative conditioning and apheresis and carry one-time list prices of roughly $2.2M and $3.1M.
Against these curative-intent therapies sits a disease-modifying backbone that remains under-deployed. Generic hydroxyurea — proven decades ago to cut painful crises by about 44% — still reaches only 25–30% of eligible patients. L-glutamine (Endari) and the P-selectin inhibitor crizanlizumab (Adakveo) round out the oral and infused options. The field narrowed in 2024 when Pfizer withdrew voxelotor (Oxbryta) from the market over a safety signal; FDA Drugs@FDA now lists it as discontinued, and it is excluded from this in-market landscape. The commercial contest is therefore two-tiered: a high-cost, logistically demanding gene-therapy duel layered over a legacy backbone with a large, addressable adherence gap.
FDA-approved and withdrawn sickle cell disease therapies — United States, 2026
| Drug (Brand / INN) | Mechanism | Company | FDA Status | Key Result | Cost / Burden |
|---|---|---|---|---|---|
| Casgevy (exagamglogene autotemcel) | CRISPR-Cas9 gene editing — HbF induction (one-time, autologous) | Vertex / CRISPR Therapeutics | Approved Dec 2023 (age ≥12) | CLIMB SCD-121: 29/30 evaluable (97%) free from severe VOCs ≥12 months | ~$2.2M one-time list price; myeloablative busulfan conditioning + apheresis |
| Lyfgenia (lovotibeglogene autotemcel) | Lentiviral gene addition — anti-sickling β-globin (one-time, autologous) | bluebird bio | Approved Dec 2023 (age ≥12) | Complete resolution of vaso-occlusive events in the majority of treated patients (FDA label) | ~$3.1M one-time list price; boxed warning for hematologic malignancy; conditioning + apheresis |
| Hydroxyurea (generic) | Oral HbF inducer / cytoreductive | Multiple generics | Approved 1998; backbone SoC | MSH: painful crises reduced ~44%, acute chest syndrome ~50% | ~$600–1,200/year; only 25–30% of eligible patients treated |
| Endari (L-glutamine) | Oral antioxidant / oxidative-stress reducer | Emmaus Life Sciences | Approved 2017 (age ≥5); marketed | Reduced frequency of sickle-cell crises vs placebo (Phase 3) | Oral chronic therapy |
| Adakveo (crizanlizumab) | P-selectin inhibitor (IV, monthly) | Novartis | Approved Nov 2019 (full approval, SUSTAIN); marketed | Reduced annual vaso-occlusive crisis rate vs placebo (SUSTAIN) | IV infusion; post-approval STAND trial did not confirm benefit (EU authorisation withdrawn 2023) |
| Oxbryta (voxelotor) — WITHDRAWN | Oral HbS polymerisation inhibitor | Pfizer / Global Blood Therapeutics | Withdrawn 2024 — FDA status Discontinued | No longer marketed; voluntarily withdrawn over a safety signal | Not available |
Sources: FDA Drugs@FDA and product labeling (approval status, the December 2023 gene-therapy approvals, and the 2024 Oxbryta discontinuation); CLIMB SCD-121, NEJM 2024 (PMID 38661449); Multicenter Study of Hydroxyurea, NEJM 1995 (PMID 7715639). Gene-therapy list prices per manufacturer announcements.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How do the two one-time gene therapies (Casgevy, Lyfgenia) differentiate on mechanism, efficacy, safety and price, and which severe-SCD patients are eligible? • CRISPR vs lentiviral mechanism • CLIMB SCD-121 vs Lyfgenia efficacy • Lyfgenia boxed warning for hematologic malignancy • conditioning and apheresis burden • eligibility (≥2 severe VOCs/year, age ≥12)
- What is the role of the disease-modifying backbone (hydroxyurea, L-glutamine, crizanlizumab) now that gene therapy has arrived, and where is the underutilisation gap? • Hydroxyurea 25–30% utilisation gap • L-glutamine and crizanlizumab positioning • the voxelotor (Oxbryta) withdrawal and its effect on the oral options
- Which agents remain in-market versus withdrawn, and how does the competitive map shift through 2026? • Verified FDA status of every agent • the voxelotor withdrawal • post-approval confirmatory-evidence questions (crizanlizumab) • the Casgevy–Lyfgenia contest
What's inside
-
1 · Market Map: Gene Therapy vs Disease-Modifying Backbone 4 pp
- Two one-time gene therapies approved December 2023 for patients 12+, layered over a legacy hydroxyurea/L-glutamine/crizanlizumab backbone
- Why the market splits into a high-cost curative-intent gene-therapy duel and a decades-old disease-modifying backbone with a large adherence gap
-
2 · Drug Profiles: Casgevy, Lyfgenia & the Legacy Agents 8 pp
- Casgevy's CRISPR-Cas9 BCL11A editing vs Lyfgenia's lentiviral anti-sickling β-globin gene addition — mechanism, company and pivotal-trial detail for both
- Hydroxyurea, L-glutamine (Endari) and crizanlizumab (Adakveo) profiles, including hydroxyurea's ~44% crisis reduction in the MSH trial
-
3 · The Casgevy–Lyfgenia Gene-Therapy Contest 4 pp
- CLIMB SCD-121: 97% of evaluable Casgevy patients free from severe vaso-occlusive crises for 12+ months, against Lyfgenia's boxed warning for hematologic malignancy
- Casgevy's ~$2.2M one-time list price against Lyfgenia's ~$3.1M — the highest single-dose prices in the sickle cell market
-
4 · Hydroxyurea Underutilisation & the Oral Disease-Modifiers 4 pp
- Generic hydroxyurea cuts painful crises by roughly 44% yet reaches only 25–30% of eligible patients, the single largest addressable gap in the market
- Why Pfizer's 2024 withdrawal of voxelotor (Oxbryta) over a safety signal narrowed the oral disease-modifier field to hydroxyurea and L-glutamine
-
5 · Access, Cost & Site-of-Care Constraints 4 pp
- Weeks of myeloablative busulfan conditioning and apheresis before either gene-therapy infusion, a site-of-care burden distinct from any oral or infused agent
- Crizanlizumab's post-approval STAND trial failed to confirm benefit, leading to its 2023 EU authorisation withdrawal even as it remains marketed in the US
-
6 · Pipeline & Next-Generation Approaches 3 pp
- The bar future SCD therapies must clear: CLIMB SCD-121's 97% VOC-free rate at $2.2–3.1M one-time cost, without myeloablative conditioning or boxed safety warnings
- Where the 70–75% of hydroxyurea-eligible patients not yet treated leaves room for next-generation approaches to close the adherence gap before gene therapy
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom brief delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this brief
AXLRx delivers US sickle cell disease competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
- 1. Submit your requestUse the intake form to specify your indication, geography, and commercial question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
- 3. DeliveryResearch-verified brief in 72 hours with optional analyst readout.
How AXLRx builds this brief
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Sickle Cell Disease Competitive Intelligence sources: FDA Drugs@FDA and product labeling (approval status, the December 2023 gene-therapy approvals, and the 2024 voxelotor withdrawal), the pivotal trial publications in the New England Journal of Medicine (CLIMB SCD-121 for exa-cel; the Multicenter Study of Hydroxyurea), and ClinicalTrials.gov registrations.
- Casgevy and Lyfgenia approval status and indications verified live against FDA product labeling (December 2023 approvals)
- exa-cel efficacy verified against CLIMB SCD-121, N Engl J Med 2024 (PMID 38661449) — 97% of evaluable patients free from severe VOCs ≥12 months
- Hydroxyurea efficacy verified against the Multicenter Study of Hydroxyurea, N Engl J Med 1995 (PMID 7715639)
- Voxelotor (Oxbryta) confirmed withdrawn — FDA Drugs@FDA marketing status 'Discontinued' (Pfizer withdrawal, 2024); excluded from the in-market landscape
Frequently asked questions
Landscape What therapies are approved for sickle cell disease in the US?
Two one-time gene therapies were approved in December 2023: Casgevy (exagamglogene autotemcel, a CRISPR-Cas9 edit) and Lyfgenia (lovotibeglogene autotemcel, a lentiviral gene addition), both for patients aged 12 and older with recurrent vaso-occlusive disease. The disease-modifying backbone comprises generic hydroxyurea, L-glutamine (Endari) and the P-selectin inhibitor crizanlizumab (Adakveo). Voxelotor (Oxbryta) was withdrawn from the market in 2024 and is no longer available.
Gene therapy How do Casgevy and Lyfgenia differ?
Casgevy uses CRISPR-Cas9 to edit the BCL11A enhancer and reactivate fetal hemoglobin; in CLIMB SCD-121, 29 of 30 evaluable patients (97%) were free from severe vaso-occlusive crises for at least 12 months. Lyfgenia adds a functional anti-sickling β-globin gene via a lentiviral vector and carries an FDA boxed warning for hematologic malignancy. Both require myeloablative conditioning and apheresis, and carry one-time list prices of roughly $2.2M and $3.1M respectively.
Deliverables What formats are included with every brief?
Every commissioned brief includes three deliverables: a 20–30 page PDF analyst brief with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.